Becton, Dickinson and Company (NYSE:BDX) Stock Has Consensus Target Price of $187.67

Posted by Francis Steltz on Sep 25th, 2026

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) has been given a consensus recommendation of “Hold” by the seventeen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $187.67.

BDX has been the subject of a number of research reports. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research report on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Finally, Bank of America increased their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st.

Read Our Latest Stock Report on Becton, Dickinson and Company

Insider Activity

In other news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,830 shares of company stock worth $1,251,894. 0.40% of the stock is owned by corporate insiders.

Institutional Trading of Becton, Dickinson and Company

Large investors have recently made changes to their positions in the stock. Brown Lisle Cummings Inc. boosted its position in shares of Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after acquiring an additional 54 shares during the period. Elevation Point Wealth Partners LLC increased its position in Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC raised its stake in Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after purchasing an additional 62 shares during the last quarter. NorthRock Partners LLC boosted its holdings in Becton, Dickinson and Company by 2.0% in the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock valued at $499,000 after purchasing an additional 65 shares during the period. Finally, QRG Capital Management Inc. boosted its holdings in Becton, Dickinson and Company by 0.7% in the 2nd quarter. QRG Capital Management Inc. now owns 8,798 shares of the medical instruments supplier’s stock valued at $1,331,000 after purchasing an additional 65 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.7%

BDX stock opened at $179.45 on Friday. The company has a 50 day moving average of $177.60 and a two-hundred day moving average of $160.93. The company has a market cap of $49.45 billion, a price-to-earnings ratio of 54.05, a PEG ratio of 12.90 and a beta of 0.21. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.